Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Is it fair to assume as we are very close to the start of November, and to be so confident they will start clinical trials this year intimates they have already received a green light ref CTA, just awaiting official sign off?
Just a minor point, if you have already or are considering investing in SAR shares, and in general any AIM share and are not already aware of the huge risks associated with these investments. Then I don’t believe you should even consider putting your money into this market.
Looking at the gov uk site, I wouldn’t be surprised if the application takes longer than some expect. I believe our compound could well fall into one of the stated categories.
Applications that need expert advice
For certain trials, we will seek advice from the Clinical Trials,
We may refer other applications for expert advice if we identify issues during the assessment process. Examples of trials where expert advice may be needed include first-in-human (FIH) trials with novel compounds where the:
mode of action involves a target that is connected to multiple signalling pathways (target with pleiotropic effects), e.g. leading to various physiological effects or targets that are ubiquitously expressed
compound acts (directly or indirectly) via a cascade system where there may be an amplification effect which might not be sufficiently controlled by a physiological feedback mechanism
compound acts (directly or indirectly) via the immune system with a target or mechanism of action which is novel or currently not well characterised
is novelty in the structure of the active substance e.g. a new type of engineered structural format such as those with enhanced receptor interaction as compared with the parent compound
level of expression and biological function of the target receptor may differ between healthy individuals and patients with the relevant disease
is insufficient available knowledge of the structure, tissue distribution, cell specificity, disease specificity, regulation, level of expression and biological function of the human target, including down-stream effects
https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in-the-uk#assessment-of-your-submission
Colbalt, I agree the SP is significantly lower than its peak of last year. However it has risen 200% over the last 5 years, I doubt many pensions pots have gained 40% consistently for the past 5 years. Its all relative, property is very likely to drop in value in London over the next year or two. Does that make bricks and mortar a pile of worthless rubble??
"A recent study has revealed that constantly moaning and whinging about a decision you, personally made to buy and hold a share or stock is a sign of boringness. It was also noted that this personality trait was common with those who constantly seek attention. Coupled with a superiority complex they often develop a ridiculous believe that they are more intelligent than the scientific BOD who run the company they have invested in. Sadly more often than not they personally couldn't run a bath, never a mind a PLC. However there is light at the end of this very dark tunnel, Professor Fooking Obvious of Frankfurt University, who has been studying Clown Syndrome for several years, stated all they have to do is grow a backbone and sell their shares."
Gilead paid $510 million in cash for YM BioSciences only drug Momelotinib. The drug, was reported to be an embarrassing dud in the clinic, and Sierra agreed to pay Gilead only $3 million in cash for the asset.
GSK have since purchased Sierra for $1.9 Billion, and in essence all they have is Momeltinib.
So Gilead must have misinterpreted the potential.
The article below explains why a return to SAR could be best for the molecule and all those involved in its advancement.
https://endpts.com/remember-momelotinib-gilead-unloads-rights-to-its-shelved-jak-inhibitor-for-token-3m-payment/
Surfie, I watched my £30k investment drop to £8k and then peak at circa £380k. Be patient you state you’ve been invested a few months, that’s a very, very short time in pharma discovery stocks.
Groverlad - good to see you back mate. Always a good sign, the harder you try to bring the SP down, the higher it climbs.
Although most people consider you to be like a genital wart, I view you as a four leaf clover. Hang in there kid. Xx